

Dated: 10th February 2025

To, BSE Limited Corporate Relations Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Security Code: 543327	To, National Stock Exchange of India Ltd. Corporate Relations Department Exchange Plaza, Block G,C/1, Bandra Kurla Complex, Bandra (E), Mumbai –400 051 Symbol: EXXARO
---	---

Dear Sir/Madam,

Sub: Newspaper Advertisements - Unaudited Financial Results of the company for the quarter & Nine Months ended 31.12.2024

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the unaudited Financial Results of the Company for the quarter & nine months ended on 31st December 2024, published in Financial Express (All Editions) and Financial Express (Ahmedabad Edition), both dated on 10th February, 2025.

Financial Statement for the quarter ended as mentioned above has also been published on website (www.exxarotiles.com) of the Company.

We are requested to kindly take the same on record.

Yours Faithfully

For Exxaro Tiles Limited

Mr. Mukeshkumar B. Patel
Managing Director
DIN: 01944968

Encl: As above

EXXARO TILES LIMITED

Corporate Office: 1201, D-Block, Ganesh Glory11, Near BSNL Office, S.G Highway, Jagatpur, Ahmedabad - 382470 | 079 3500 5555.

REG. Office & Unit 2: Survey No. 169 & 170, Vavdi Harsol Road, at & Po.: Mahelav, Taluka: Talod, Sabarkantha - 383305, Gujarat, India.

Unit 1: Block No. 204/205, Opp. Hanuman Temple, Near Mahuvad Turning, At & Po. Dabhasa, Tal.Padara, Dist. Vadodara - 391440 Gujarat, India.

🌐 www.exxarotiles.com 📧 info@exxarotiles.com ☎ +91 87585 72121 | **CIN:** L26914GJ2008PLC052518



Kirloskar Ferrous Industries Limited

A Kirloskar Group Company

Registered Office: 'One Avante', Level 5, Karve Road, Kothrud, Pune 411038, Maharashtra**CIN:** L27101PN1991PLC063223**NOTICE TO THE MEMBERS**

This is to inform that the Board of Directors of the Company at its meeting held on 4 February 2025 has declared an Interim Dividend of ₹ 3 per equity share with nominal value of ₹ 5 each (i.e. 60 percent) for the financial year 2024-2025 and has fixed the Record Date as **Friday, 14 February 2025** for determining the list of members entitled to receive dividend. Interim dividend will be paid on or before 3 March 2025 through various modes of payment such as Direct Credit / RTGS / NEFT / NECS / Demand Drafts / Dividend Warrants / Banker's Cheques or any other mode available with the bank, as the case may be.

Pursuant to provisions of the Income-tax Act, 1961 ('the Act') as amended from time to time; dividend declared and paid by a company is taxable in the hands of the shareholders and the company is required to deduct tax at source (TDS) at the applicable rates from dividend payable to the shareholders and deposit the same to the credit of the Central Government.

Tax rate applicable to a shareholder depends upon residential status and classification as per the provisions of the Act. All Members are hereby requested to update at the earliest before **14 February 2025** any change in residential status and/or category with depository participants (in case of equity shares held in electronic form) or with the RTA i.e. "MUFG Intime India Private Limited" [earlier known as Link Intime India Private Limited] (in case of equity shares held in physical form), as may be applicable.

A detailed communication regarding the withholding tax on dividend along with necessary annexures and guidance on registration / updation of details of bank account to receive dividend has been sent on 7 February 2025 by email to those Members, whose email IDs are registered with the Depository Participants or with the RTA, as the case may be.

Application forms for claiming Nil or less rate of TDS by Resident Shareholders [such as Form 15G / Form 15H in case of individuals and self-declaration by entities] and by Non Resident Shareholders [such as Form 10F and self-declaration] can be downloaded from the website of the RTA viz. <https://web.in.mfpm.fug.com/formsreg/submission-of-form-15g-15h.html>

To enable us to determine appropriate TDS / Withholding tax rate applicable, you should upload necessary documents at <https://web.in.mfpm.fug.com/formsreg/submission-of-form-15g-15h.html> or send by email to kfiiinvestor@kirloskar.com before 14 February 2025.

No communication on tax determination / deduction shall be considered after 14 February 2025.

A Member of the Company, holding equity shares in physical form, can register or update details of bank account with the RTA by sending signed copies of KYC Forms (viz. ISR-1, ISR-2, SH13 / ISR-3 as applicable) along with supporting documents to the email ID pune@linkintime.co.in Aforesaid forms can be downloaded from the weblink of the RTA at <https://web.in.mfpm.fug.com/KYC/index.html> If a Member of the Company holding equity shares in physical form has updated earlier KYC details with the RTA, there is no requirement to update KYC details again.

A Member of the Company holding equity shares in electronic form can register or update details of bank account with respective Depository Participant.

Documents furnished by the Members shall be subject to review and examination by the Company. The Company reserves the right to reject documents in case of any discrepancy or documents are found to be incomplete.

For Kirloskar Ferrous Industries Limited

Place : Pune
Date : 8 February 2025

Sd/-
Mayuresh Gharpure
Company Secretary

Tel: +91 20 6906 5040

Email: kfiiinvestor@kirloskar.com Website: www.kirloskarferrous.com

Mark bearing word "Kirloskar" in any form as a suffix or prefix is owned by Kirloskar Proprietary Limited and Kirloskar Ferrous Industries Limited is the Permitted User



(This is only an advertisement for information purposes and not a prospectus announcement)

SHANMUGA HOSPITAL LIMITED

(Erstwhile known as Shanmuga Hospital Private Limited)

Our company was originally incorporated as a Private Limited Company under the name "Shanmuga Hospital Private Limited" on June 26, 2020, in accordance with the Companies Act, 2013. We received a fresh certificate of incorporation, bearing the corporate identification number U85110T22020PTC033974, from the Registrar of Companies, Central Registration Centre. Subsequently, our company converted into a public limited company, resulting in a name change to "Shanmuga Hospital Limited." This alteration was formally recorded in a new Certificate of Incorporation dated June 06, 2024, with the Corporate Identification Number U85110T22020PTC033974, issued by the Registrar of Companies, Central Processing Centre. For further details of change in name and registered office of our company, please refer to section titled "Our History and Certain Corporate Matters" beginning on page no 159 of the Prospectus.

Registered & Corporate Office: 51/24, Saradha College Road, Salem - 636007, Tamil Nadu, India
Contact Person: Mr. Veera Pratap Reddy Gandluru, Company Secretary & Compliance Officer; Tel No: +91 427 2706674, E-Mail ID: cs@smrft.org
Website: www.shanmugahospital.com; **CIN:** U85110T22020PTC033974

OUR PROMOTERS: (I) DR. PANNEERSELVAM PALANIAPPAN SHANMUGAM; (II) DR. PRABU SANKAR PANNEERSELVAM; (III) DR. PRIYADHARSHNI DHANDAPANI; AND (IV) MRS. JAYALAKSHMI PANNEERSELVAM

The issue is being made in accordance with Chapter IX of the SEBI ICDR Regulations (IPO of Small and Medium Enterprises) and the equity shares are proposed to be listed on SME platform of BSE Limited (BSE SME).

INITIAL PUBLIC OFFER OF UP TO 38,18,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF SHANMUGA HOSPITAL LIMITED (THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹54/- PER EQUITY SHARE, INCLUDING A SHARE PREMIUM OF ₹44/- PER EQUITY SHARE (THE "ISSUE PRICE"), AGGREGATING TO ₹ 2,061.72 LAKHS ("THE ISSUE"), OF WHICH 1,92,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹54/- PER EQUITY SHARE, AGGREGATING TO ₹ 103.68 LAKHS WILL BE RESERVED FOR SUBSCRIPTIONS BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 36,26,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹54/- PER EQUITY SHARE, AGGREGATING TO ₹ 1,958.04 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.05% AND 26.64% RESPECTIVELY OF THE POST ISSUE PAIDUP EQUITY SHARE CAPITAL OF THE COMPANY.

All the investors applying in a public issue shall use only Application Supported by Blocked Amount (ASBA) facility for making payment providing details about the bank account which will be blocked by the Self Certified Syndicate Banks ("SCSBs") as per the SEBI Master Circular No. SEBI/HO/CFD/PoD-1/P/CIR/2024/0154 dated November 11, 2024. As an alternate payment mechanism, Unified Payments Interface (UPI) has been introduced (vide SEBI Circular Ref. SEBI/HO/CFD/DIL2/CIR/P/2018/138 dated November 1, 2018) and SEBI Circular No. SEBI/HO/CFD/DCR2/CIR/P/2019/133 dated November 08, 2019) as a payment mechanism in a phased manner with ASBA for applications in public issues by retail individual investors. For further details, please refer to section titled "Issue Procedure" beginning on page 263 of the Prospectus. As per SEBI Master Circular No. SEBI/HO/CFD/PoD-1/P/CIR/2024/0154 dated November 11, 2024, all ASBA applications in Public Issues shall be processed only after the application money is blocked in the investor's bank accounts. In case of delay, if any in refund, our Company shall pay interest on the application money at the rate of 15% per annum for the period of delay.

THIS ISSUE IS BEING MADE IN TERMS OF CHAPTER IX OF THE SEBI (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018 (THE "SEBI ICDR REGULATIONS") READ WITH RULE 19(2)(b)(i) OF SCRR, AS AMENDED. THIS ISSUE IS A FIXED PRICE ISSUE AND ALLOCATION IN THE NET OFFER TO THE PUBLIC WILL BE MADE IN TERMS OF REGULATION 253(2) OF THE SEBI (ICDR) REGULATIONS, 2018. (For further details please see "The Issue" beginning on page no. 52 of the Prospectus.) A copy of Prospectus is delivered for filing to the Registrar of Companies as required under sub-section 4 of Section 26 of the Companies Act, 2013.

For further details please refer the section titled "ISSUE PROCEDURE" beginning on page 263 of the Prospectus

FIXED PRICE ISSUE AT ₹ 54/- PER EQUITY SHARE

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS 5.4 TIMES OF THE FACE VALUE OF THE EQUITY SHARES.

THE APPLICATION MUST BE FOR A MINIMUM OF 2,000 EQUITY SHARES AND IN MULTIPLES OF 2,000 EQUITY SHARES THEREAFTER.

FOR FURTHER DETAILS PLEASE REFER TO "SECTION XI - ISSUE INFORMATION" BEGINNING ON PAGE 254 OF THE PROSPECTUS.

ISSUE PROGRAMME**ISSUE OPENS ON : THURSDAY, FEBRUARY 13, 2025**
ISSUE CLOSING ON: MONDAY, FEBRUARY 17, 2025

Bid Opening Date	February 13, 2025	Initiation of Unblocking of Funds/refunds (T+2 Day)	February 20, 2025
Bid Closing Date (T day)	February 17, 2025	Credit of Equity Shares to demat accounts of Allottees (T+2 Day)	February 20, 2025
Finalization of basis of allotment with the Designated Stock Exchange/Allotment of Securities (T+1 day)	February 18, 2025	Commencement of Trading of Equity Shares on the Stock Exchange (T+ 3 days)	February 21, 2025
Timelines for Submission of Application (T is issue closing date)			
Application Submission by Investors		Bid Modification: From Issue opening date up to 5 pm on T day	
Electronic Applications (Online ASBA through 3-in-1 accounts) – Up to 5 pm on T day		Validation of bid details with depositories: From Issue opening date up to 5 pm on T day	
Electronic Applications (Bank ASBA through Online channels like Internet Banking, Mobile Banking and Syndicate UPI ASBA etc) – Up to 4 pm on T day.		UPI Mandate Acceptance time: T day - 5 pm	
Electronic Applications (Syndicate Non-Retail, Non-Individual Applications) – Up to 3 pm on T day.		Issue Closure	
Physical Applications (Bank ASBA) – Up to 1 pm on T day.		T Day - 4 pm for QIB and NII Categories	
Physical Applications (Syndicate Non-Retail, Non-Individual Applications of QIBs and NII) – Up to 12 pm on T day and Syndicate members shall transfer such applications to banks before 1 pm on T day.		T Day - 5 pm for Retail and Other Reserved Categories	

ASBA*Simple, Safe, Smart way of Application!!
Mandatory in public issue. No cheque will be accepted

now available in ASBA for retail individual investors.

*ASBA is a better way of applying to issues by simply blocking the fund in the bank account. For further details check section on ASBA below.

*ASBA has to be availed by all the Investors. UPI may be availed by Retail Individual Investors.

For details on the ASBA and UPI process, please refer to the details given in ASBA form and General Information Documents and also please refer to the section "Issue Procedure" beginning on page 263 of the Prospectus.

CONTENTS OF THE MEMORANDUM OF THE COMPANY AS REGARDS TO ITS OBJECTS: For information on the main objects of the Company, please see "Our History And Certain Other Corporate Matters" on page 159 of the Prospectus and Clause III of the Memorandum of Association of the Company. The Memorandum of Association of the Company is a material document for inspection in relation to the issue. For further details, please see "Material Contracts and Documents for Inspection" on page 297 of the Prospectus.

AMOUNT OF SHARE CAPITAL OF THE COMPANY AND CAPITAL STRUCTURE: The authorised share capital, issued, subscribed and paid up share capital of the Company as on the date of the Prospectus is as follows: The Authorised Share Capital of the Company is ₹ 1,400.00 lakhs divided into 1,40,00,000 Equity Shares of ₹10/- each. The Issued, Subscribed and Paid-up share capital of the Company before the Issue is ₹ 979.50 Lakhs divided into 97,95,000 Equity Shares of ₹10/- each. Proposed Post issue capital: ₹ 1,361.30 Lakhs divided into 1,36,13,000 Equity Shares of ₹10/- each. For details of the Capital Structure, see the section "Capital Structure" on the page 64 of the Prospectus.

NAMES OF THE SIGNATORIES TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AND THE NUMBER OF EQUITY SHARES SUBSCRIBED BY THEM: Given below are the names of the signatories of the Memorandum of Association of the Company and the number of Equity Shares subscribed for by them at the time of signing of the Memorandum of Association: Dr. Panneeselvam Palaniappan Shanmugam, Dr. Prabu Sankar Panneeselvam, Mrs. Jayalakshmi Panneeselvam, and Dr. Priyadharsini Dhandapani were each allotted 2,000 equity shares having face value of ₹100/- each, aggregating to 8,000 equity shares.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 FINSHORE MANAGEMENT SERVICES LIMITED Andank Building, Block-A, 2nd Floor, Room No. 207, 227 A, J.C. Bose Road, Kolkata-700020, West Bengal, India Telephone: 033 - 2289 5101 / 4603 2561 Email: info@finshoregroup.com Contact Person: Mr. S. Ramakrishna Iyengar Website: www.finshoregroup.com Investor Grievance Email: investors@finshoregroup.com SEBI Registration No: INM000012185 CIN No: U74900WB2011PLC169377	 INTEGRATED REGISTRY MANAGEMENT SERVICES PRIVATE LIMITED No 30, Ramana Residency, 4th Cross, Sampige Road, Malleswaram, Bengaluru - 560003, India Telephone: 080-23460815/816/817/818 Email: smelpo@integratedreg.in Contact Person: S Giridhar Website: www.integratedregistry.in Investor Grievance Email: gin@integratedreg.in SEBI Registration Number: INR000000544 CIN: U74900TN2015PTC101466	Mr. Veera Pratap Reddy Gandluru Company Secretary & Compliance Officer SHANMUGA HOSPITAL LIMITED Registered Office: 51/24, Saradha College Road, Salem - 636007, Tamil Nadu, India Contact No: +91 427 2706674 Email ID: cs@smrft.org Website: www.shanmugahospital.com Investors may contact our Company Secretary and Compliance Officer and / or the Registrar to the Issue and / or the Lead Manager, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, credit of allotted Equity Shares in the respective beneficiary account or refund orders, etc.

Availability of Prospectus: Investors should note that investment in Equity Shares involves a high degree of risk and investors are advised to refer to the Prospectus and the Risk Factors contained therein, before applying in the Issue. Full copy of the Prospectus will be available at the website of SEBI at www.sebi.gov.in; the website of the Stock Exchange at www.bseindia.com, the website of Lead Manager at www.finshoregroup.com and website of Issuer Company at www.shanmugahospital.com

Availability of Application form: Application forms can be obtained from the Registered Office of SHANMUGA HOSPITAL LIMITED and the Lead Manager to the Issue - FINSHORE MANAGEMENT SERVICES LIMITED. Application Forms can be obtained from the website of Stock Exchange at www.bseindia.com and the Designated Branches of SCSBs, the list of which is available on the website of SEBI.

Applications Supported by Blocked Amount (ASBA): Investors have to compulsorily apply through the ASBA process. ASBA has to be availed by all the investors. The investors are required to fill the application form and submit the same to the relevant SCSBs at the specific locations or registered brokers at the broker centres or RTA or DP's. The SCSBs will block the amount in the account as per the authority contained in application form. On allotment, amount will be unblocked and account will be debited only to the extent required to be paid for allotment of shares. Hence, there will be no need of refund. The ASBA application forms can also be downloaded from the website of BSE. ASBA application forms can be obtained from the Designated Branches of SCSBs, the list of banks that are available on website of SEBI at www.sebi.gov.in and website of Stock Exchange at www.bseindia.com. For more details on ASBA process, please refer to the details given in application forms and Prospectus and also please refer to the Section "Issue Procedure" beginning on page 263 of the Prospectus.

UNIFIED PAYMENTS INTERFACE (UPI): Investors are advised to carefully refer SEBI Master Circular bearing reference no. SEBI/HO/CFD/PoD-1/P/CIR/2024/0154 dated November 11, 2024 for details relating to use of Unified Payments Interface (UPI) as a payment mechanism with Application Supported by Block Amount (ASBA) for applications in public issues.

BANKER TO THE ISSUE/SPONSOR BANK: ICICI Bank Limited

Investors should read the Prospectus carefully, including the Risk Factors beginning on page 23 of the Prospectus before making any investment decision.

The Lead Manager associated with the Issue has handled 29 SME public issues and Nil Main Board public issue during the current financial year and three financial years preceding the current Financial Year, out of which 7 SME public issues closed below the issue price on the listing date.

Type	FY 2024-25*	FY 2023-24	FY 2022-23	FY 2021-22	Total
SME IPO	5	5	12	7	29
Main Board IPO	-	-	-	-	-
Total	5	5	12	7	29
Issue closed Below Issue Price on Listing Day	-	-	5	2	7
Issue closed above Issue Price on Listing Day	5	5	7	5	22

* Status as on 05-02-2025

For SHANMUGA HOSPITAL LIMITED
On behalf of the Board of DirectorsSd/-
Prabu Sankar Panneeselvam
Executive Director & CEO
DIN: 08772888Place : Salem, Tamil Nadu
Date : February 08, 2025

SHANMUGA HOSPITAL LIMITED is proposing, subject to market conditions and other considerations, a public issue of its Equity Shares and has filed the Prospectus with the Registrar of Companies, Coimbatore. The Prospectus is available on the website of the SEBI at www.sebi.gov.in, the website of the Lead Manager at www.finshoregroup.com, website of the BSE at www.bseindia.com and website of Issuer Company at www.shanmugahospital.com. Investor should note that investment in Equity Shares involves a high degree of risk. For details, investors should refer to and rely on the Prospectus, including the section titled "Risk Factors" as appearing in the Prospectus. The Equity Shares have not been and will not be registered under the US Securities Act (the "Securities Act") or any state securities laws in United States and will not be issued or sold within the United States or to, or for the account or benefit of "U.S. persons" (as defined in Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, 1933.

EXXARO TILES LIMITED

Corporate Office: 1201, D-Block, Ganesh Glory 11, Nr. BSNL Office, S.G. Highway, Jagatpur, Ahmedabad-382 470, Ph.No.: 079-3500 5555.

Regd. Office & Unit 2: Survey No.-169 & 170, Vaidi Harsoil Road, at & Po.: Dabhaha, Tal: Padara, Dist. Vadodara-391 440, Gujarat, India.

www.exxarotiles.com info@exxarotiles.com +91 87585 72121

CIN: L26914GJ2008PLC052518

**EXTRACT OF STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 31ST DECEMBER 2024**

(Rs in Lakhs except per shares data)

Sr. No.	Particular	Quarter ended	Nine Months ended	Nine Months ended
		December 31, 2024	December 31, 2024	December 31, 2023
		(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operation	7955.93	20992.57	22338.45
2.	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	163.53	(257.39)	100.19
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	163.53	(307.39)	100.19
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	123.72	(362.76)	104.89
5.	Total Comprehensive Income for the period	134.57	(330.24)	104.13
6.	Paid up Equity Share Capital			
7.	Earnings Per Share (of ₹ 10/- each)			
1.	Basic:	0.03	(0.08)	0.02
2.	Diluted:	0.03	(0.08)	0.02

Notes: 1. Summarized Standalone unaudited Financial performance of the Company is as under: (Rs in Lakhs)

Sr. No.	Particular	Standalone		
		Quarter ended	Nine Months ended	Nine Months ended
		December 31, 2024	December 31, 2024	December 31, 2023
		(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operation	7913.97	20928.59	22340.98
2.	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	119.51	(322.73)	103.34
3.	Net Profit / (Loss) for the period after tax (after tax, Exceptional and/or Extraordinary items)	90.79	(374.86)	108.04
4.	Total Comprehensive Income for the period	101.63	(342.34)	107.28

2. The Company's financial results for the quarter and Nine months ended December 31, 2024 have been reviewed by the Audit Committee and subsequently approved & taken on record by the Board of Directors of the Company at its meeting held on 08th February 2025.

3. The Unaudited financial results for the quarter and Nine months ended December 31, 2024 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of The Companies Act, 2013 and other recognized accounting practices and the policies to the extend applicable.

4. The Company's Operations fall under a single segment "Manufacturing and Trading of refractory ceramic products (Vitrified Tiles)". Hence, Segment reporting is not applicable as per Indian Accounting Standard (Ind AS) - 108 - Segment Reporting.

5. During the year, the Company on 13 December 2024 ("Record Date"), sub-divided/split of existing Equity Shares of the Company from 1(One) Equity Share having face value of Rs.10/- (Rupees Ten Only) each fully paid up, into 10 (Ten) Equity Share of the face value of Rs.1/- (One) each fully paid up. Accordingly, earnings per share of comparative periods presented has been calculated based on number of shares outstanding in respective periods as increased by sub-divided/split of shares.

6. Figures of previous reporting periods have been regrouped/reclassified wherever necessary to correspond with the figures of the current reporting period.

7. The above is an extract of the detailed of Quarterly and half yearly Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (LODR) Regulation, 2015. The full format of the Quarterly and half yearly Financial Results are available on the website of the BSE (www.bseindia.com), NSE (www.nseindia.com) and of the Company (www.exxarotiles.com).

On behalf of the Board of Director
For, Exxaro Tiles LimitedSd/- Mukeshkumar B. Patel
Managing DirectorDate: 08th February, 2025
Place: AhmedabadTHE
BUSINESS
DAILY.

FINANCIAL EXPRESS

FOR
DAILY
BUSINESS.